Get the Stockscreener App
13.68
1.79%
-0.25
After Hours:
13.68
Korro Bio Inc stock is traded at $13.68, with a volume of 77,274.
It is down -1.79% in the last 24 hours and up +6.87% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
See More
Previous Close:
$13.93
Open:
$13.87
24h Volume:
77,274
Relative Volume:
0.32
Market Cap:
$197.30M
Revenue:
$6.39M
Net Income/Loss:
$-117.26M
P/E Ratio:
-1.0961
EPS:
-12.4807
Net Cash Flow:
$-79.08M
1W Performance:
+1.63%
1M Performance:
+6.87%
6M Performance:
-73.36%
1Y Performance:
+2.09%
1-Day Range:
$13.33
$14.07
1-Week Range:
$12.50
$14.54
52-Week Range:
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
60 FIRST STREET, CAMBRIDGE
Compare KRRO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
13.68 | 200.91M | 6.39M | -117.26M | -79.08M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-17-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-29-26 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-29-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-29-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-28-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jan-28-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-13-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-13-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-13-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-13-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-13-25 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Nov-13-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-16-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Raymond James | Strong Buy |
| Aug-14-24 | Initiated | William Blair | Outperform |
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule - National Today
Korro Bio reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Korro Bio hire gets stock option for 15,000 shares under Nasdaq rule - Stock Titan
Block Trades: Does Korro Bio Inc have pricing powerWeekly Investment Summary & Reliable Breakout Forecasts - baoquankhu1.vn
Lynx1 Capital Management LP Increases Stake in Korro Bio Inc - GuruFocus
Ideas Watch: Is Korro Bio Inc stock a good pick for beginners2026 Institutional & Weekly High Conviction Trade Ideas - baoquankhu1.vn
KRRO|Korro Bio Inc|Price:13.460|Chg%:-0.45 - TradingKey
Analyst Upgrade: Is Korro Bio Inc stock overvalued or fairly priced2026 Short Interest & AI Driven Price Predictions - baoquankhu1.vn
Can Lithium Americas Corp stock outperform in a bear marketWeekly Stock Recap & Reliable Momentum Entry Alerts - baoquankhu1.vn
KRRO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lynx1 Capital buys Korro Bio (KRRO) shares worth $5512 By Investing.com - Investing.com South Africa
Lynx1 Capital buys Korro Bio (KRRO) shares worth $5512 - Investing.com
Lynx1 and Weston Nichols report 1.54M shares in Korro Bio (NASDAQ: KRRO) - Stock Titan
Lynx1 fund tied to Weston Nichols adds Korro Bio (KRRO) position - Stock Titan
Fund linked to Korro Bio (KRRO) reports 1.54M shares on Form 3 - Stock Titan
Earnings Update: Can Korro Bio Inc be recession proof2026 Short Interest & Reliable Volume Spike Alerts - baoquankhu1.vn
KRRO Price Today: Korro Bio, Inc. Stock Price, Quote & Chart - MEXC Exchange
Investment Recap: Should you avoid Korro Bio Inc stock right now2026 Volume & Community Consensus Trade Signals - baoquankhu1.vn
Breakout Watch: Will Korro Bio Inc benefit from green energy policiesAnalyst Upgrade & AI Forecast Swing Trade Picks - baoquankhu1.vn
JPMorgan Chase & Co. Buys 196,079 Shares of Korro Bio, Inc. $KRRO - MarketBeat
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Shorts: What is the next catalyst for Korro Bio Inc2026 Historical Comparison & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Trading Recap: Can Korro Bio Inc disrupt its industry2026 Support & Resistance & Risk Managed Investment Signals - baoquankhu1.vn
Vanguard (KRRO) reports zero beneficial ownership after realignment - Stock Titan
Korro Bio stock gains after tough 2025new drug candidate, analyst upgrades boost outlook - MSN
[EFFECT] Korro Bio, Inc. SEC Filing - Stock Titan
Form 424B5 Korro Bio Inc For: 20 March By Investing.com - Investing.com Canada
Aug Decliners: What is the next catalyst for Korro Bio IncPortfolio Return Report & Verified Swing Trading Watchlists - baoquankhu1.vn
Form 424B5 Korro Bio Inc For: 20 March - Investing.com
Korro Bio (NASDAQ: KRRO) registers 7.65M shares for resale after $85M private placement - Stock Titan
Energy Moves: Will Korro Bio Inc stock hit new highs in YEAR2026 Geopolitical Influence & High Return Trade Opportunity Guides - baoquankhu1.vn
Korro Bio, Inc. (KRRO) reports Q4 loss, lags revenue estimates - MSN
Venrock entities cap ownership at 9.99% in Korro Bio (KRRO) Schedule 13G - Stock Titan
Korro Bio raises $85 million in private equity financing By Investing.com - Investing.com Nigeria
KRRO SEC FilingsKorro Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Korro Bio Stock Gains After Tough 2025New Drug Candidate, Analyst Upgrades Boost Outlook - Sahm
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
RBC Capital Keeps Their Hold Rating on Korro Bio (KRRO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), Korro Bio (KRRO) and Pharming Group (PHAR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Korro Bio (KRRO), Health Catalyst (HCAT) - The Globe and Mail
Korro Bio (KRRO) Losses Of US$117.3 Million Test Bullish Narratives On Profitability - simplywall.st
Korro Bio (KRRO) sellers register 7.65M common shares after $85M private placement - Stock Titan
Korro Bio (NASDAQ:KRRO) Rating Increased to Outperform at Raymond James Financial - MarketBeat
Cantor Fitzgerald raises Korro Bio stock price target on UCD confidence By Investing.com - Investing.com South Africa
Cantor Fitzgerald raises Korro Bio stock price target on UCD confidence - Investing.com Canada
Raymond James Upgrades Korro Bio to Outperform From Market Perform, Price Target is $23 - marketscreener.com
Raymond James upgrades Korro Bio stock rating on hyperammonemia pivot - Investing.com Nigeria
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):